Drug Trial Radar · NCT00401843
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Nov 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
307
Actual
Start
Nov 28, 2006
Primary completion
Aug 16, 2011
Study completion Sep 24, 2019
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Nov 22, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of Part 1 of the study is to determine the safety of the combination of Siltuximab (CNTO 328) and bortezomib (Velcade). The purpose of Part 2 of the study is to compare the length of progression free survival for those patients given CNTO 328 and bortezomib to those patients given bortezomib alone.
Conditions
- Multiple Myeloma
Interventions
SiltuximabBiological
Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during cycle 1 in Part 1. Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during 42-day Treatment Phase and 35-day Maintenance Phase in Part 2.
BortezomibDrug
Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus once every 2 weeks during cycle 1 in Part 1. Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period during 42-day treatment phase in Part 2. Bortezomib 1.3 mg/m2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) during 35-day Maintenance Phase in Part 2.
PlaceboDrug
Matching placebo will be administered as intravenous infusion once every 2 weeks during 42-day treatment phase and 35-day maintenance phase in Part 2.
DexamethasoneDrug
Dexamethasone tablet will be administered in this study at the first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles in treatment phase and maintenance phase of Part 2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free SurvivalTime frame: Randomization until disease progression or death, which ever occured first (maximum up to 5 years)
- Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)Time frame: up to 5 years
Locations
80 sites in 18 countries. Site status is shown where the registry gives one.
Site not named
Greenbrae, California
Site not named
Los Angeles, California
Site not named
Indianapolis, Indiana
Site not named
Albuquerque, New Mexico
Site not named
New York, New York
Site not named
Syracuse, New York
Site not named
Chapel Hill, North Carolina
Site not named
North Charleston, South Carolina
Site not named
Dallas, Texas
Site not named
Houston, Texas
Site not named
Madison, Wisconsin
Site not named
Antwerp, Belgium
Site not named
B-8000 Brugge, Belgium
Site not named
Brussels, Belgium
Site not named
Edegem, Belgium
Site not named
Leuven, Belgium
Site not named
Rio de Janeiro, Brazil
Site not named
Bulgaria, Bulgaria
Site not named
Pleven, Bulgaria
Site not named
Plovdiv, Bulgaria
Site not named
Calgary, Canada
Site not named
Vancouver, British Columbia, Canada
Site not named
Québec, Quebec, Canada
Site not named
Brno, Czechia
Site not named
Hradec Králové, Czechia
Site not named
Prague, Czechia
Site not named
Grenoble, France
Site not named
Lille Cedex N/a, France
Site not named
Montpellier, France
Site not named
Pierre-Bénite, France
Site not named
Vandœuvre-lès-Nancy, France
Site not named
Aschaffenburg, Germany
Site not named
Essen, Germany
Site not named
Mainz, Germany
Site not named
Münster, Germany
Site not named
Stuttgart, Germany
Site not named
Ulm, Germany
Site not named
Athens, Greece
Site not named
Budapest, Hungary
Site not named
Debrecen, Hungary
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.